描述
AZP-531 (CAS No. 1088543-62-7), also known as Livoletide or Cyclo(des-acyl ghrelin(6-13)), is a synthetic analogue of unacylated ghrelin (UAG). It has demonstrated significant potential in metabolic regulation, including the reduction of hyperphagia, weight stabilization, and improvement of glucose metabolism. In early human trials, AZP-531 was well tolerated, showed favorable pharmacokinetics suitable for once-daily dosing, promoted modest weight loss, improved glycemic control, and reduced postprandial glucose markers without increasing insulin levels. Manufactured under GMP standards with high purity (99.79%), AZP-531 assures consistency and reliability for experimental use. Intended strictly for laboratory research.
Product Specifications
Parameter | Details |
---|---|
Product Name | AZP-531 |
Synonyms | Livoletide; Cyclo(des-acyl ghrelin(6-13)) |
CAS No. | 1088543-62-7 |
Purity | ? 99.79% (GMP-grade) |
Molecular Formula | C??H??N??O?? |
Molecular Weight | Approx. 962.0 g/mol |
Mechanism | Analogue of unacylated ghrelin (UAG), metabolic regulator |
Pharmacodynamics | Regulates appetite, improves glycemic control, insulin-sparing |
Appearance | White to off-white cyclic peptide powder |
Solubility | Soluble in aqueous buffers; DMSO may aid solubility for stock solutions |
Storage Conditions | Store at –20 °C; protect from light and moisture |
Manufacturing Standard | GMP-compliant |
Applications | Metabolic disease models, neuroscience of appetite, Prader-Willi syndrome research |
Regulatory Status | For laboratory research use only |
Mechanism of Action & Research Applications
Mechanism of Action: AZP-531 mimics unacylated ghrelin, acting on metabolic and appetite-regulating pathways independent from acylated ghrelin’s orexigenic effect. It appears to restrict hunger, support glucose control without elevating insulin, and modulate metabolic signaling.
Research Applications:
-
Appetite & Feeding Behavior: Useful in models exploring hyperphagia, particularly in rare genetic conditions like Prader-Willi syndrome.
-
Glycemic Regulation: Supports study of insulin sensitivity and postprandial glucose dynamics.
-
Weight Management Therapeutics: Valuable in research for obesity and metabolic syndrome.
-
Pharmacokinetic Studies: Suitable as a peptide with favorable once-daily dosing characteristics.
Side Effects (Research Context Only)
AZP-531 is intended strictly for laboratory and preclinical model research. In early human studies, it was well tolerated, with no serious adverse effects reported. Observed outcomes included modest weight reduction and improved glucose parameters. No long-term safety data exists; handle with institutional laboratory standards.
Disclaimer
AZP-531 is strictly for laboratory research use only. It is not approved for clinical, diagnostic, or therapeutic purposes. Please use and store according to institutional safety protocols.
评价
目前还没有评价